BMJ  2006;332:368 (11 February), doi:10.1136/bmj.332.7537.368

reviews

TV

Panorama: Herceptin: Wanting the Wonder Drug

The first 150 words of the full text of this article appear below.

The latest episode of Panorama—one of the most respected investigative current affairs programmes on UK television—delved into the key issues surrounding the recent decision to make trastuzumab (Herceptin) available free on the NHS for selected women with early breast cancer. As it unravelled, the story was of policy making determined at a raw socio-political level rather than on the more traditional clinical grounds.

On one side of the debate were enthusiasts arguing that trastuzumab was a "wonder" drug, and a "must have" medicine for the early treatment of women with an aggressive form of breast cancer in which the malignant cells are HER2 (human epidermal growth factor receptor 2) positive. On the other were more wary prescribers who saw the drug as costly and of unproven value and one that still needed careful cost effectiveness and benefit/harm evaluations before the NHS could adopt it wholesale. The debate began . . . [Full text of this article]

St George's, University of London jcollier@sgul.ac.uk

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

A time for courage

Fiona Godlee
BMJ 2006 332: 0. [Extract] [Full Text] [PDF]

Patient takes her fight for trastuzumab to the High Court

Clare Dyer
BMJ 2006 332: 320. [Extract] [Full Text] [PDF]

Online poll

Find out more >>